Logo image of XOMA

XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

NASDAQ:XOMA - US98419J2069 - Common Stock

35.24 USD
-0.16 (-0.45%)
Last: 9/5/2025, 8:00:02 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to XOMA. XOMA was compared to 542 industry peers in the Biotechnology industry. XOMA has a medium profitability rating, but doesn't score so well on its financial health evaluation. While showing a medium growth rate, XOMA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year XOMA has reported negative net income.
XOMA had a negative operating cash flow in the past year.
In multiple years XOMA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: XOMA reported negative operating cash flow in multiple years.
XOMA Yearly Net Income VS EBIT VS OCF VS FCFXOMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of XOMA (-7.93%) is better than 84.50% of its industry peers.
XOMA has a Return On Equity of -19.17%. This is amongst the best in the industry. XOMA outperforms 84.87% of its industry peers.
XOMA's Return On Invested Capital of 3.73% is amongst the best of the industry. XOMA outperforms 91.70% of its industry peers.
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROIC 3.73%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMA Yearly ROA, ROE, ROICXOMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

XOMA has a Operating Margin of 21.23%. This is amongst the best in the industry. XOMA outperforms 94.83% of its industry peers.
The Profit Margin and Gross Margin are not available for XOMA so they could not be analyzed.
Industry RankSector Rank
OM 21.23%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMA Yearly Profit, Operating, Gross MarginsXOMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMA is destroying value.
XOMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XOMA has been increased compared to 5 years ago.
Compared to 1 year ago, XOMA has a worse debt to assets ratio.
XOMA Yearly Shares OutstandingXOMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMA Yearly Total Debt VS Total AssetsXOMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

XOMA has an Altman-Z score of -4.94. This is a bad value and indicates that XOMA is not financially healthy and even has some risk of bankruptcy.
XOMA has a Altman-Z score (-4.94) which is in line with its industry peers.
XOMA has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of XOMA (1.11) is worse than 77.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z -4.94
ROIC/WACC0.37
WACC10%
XOMA Yearly LT Debt VS Equity VS FCFXOMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

XOMA has a Current Ratio of 4.88. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.88, XOMA is in line with its industry, outperforming 53.14% of the companies in the same industry.
A Quick Ratio of 4.88 indicates that XOMA has no problem at all paying its short term obligations.
XOMA has a Quick ratio (4.88) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.88
XOMA Yearly Current Assets VS Current LiabilitesXOMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for XOMA have decreased strongly by -38.74% in the last year.
The Revenue has grown by 168.71% in the past year. This is a very strong growth!
XOMA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%

3.2 Future

XOMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.32% yearly.
Based on estimates for the next years, XOMA will show a very strong growth in Revenue. The Revenue will grow by 35.53% on average per year.
EPS Next Y117.66%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year78.53%
Revenue Next 2Y41.78%
Revenue Next 3Y35.53%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XOMA Yearly Revenue VS EstimatesXOMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMA Yearly EPS VS EstimatesXOMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XOMA. In the last year negative earnings were reported.
XOMA is valuated quite expensively with a Price/Forward Earnings ratio of 194.46.
XOMA's Price/Forward Earnings ratio is rather cheap when compared to the industry. XOMA is cheaper than 86.90% of the companies in the same industry.
XOMA is valuated expensively when we compare the Price/Forward Earnings ratio to 22.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 194.46
XOMA Price Earnings VS Forward Price EarningsXOMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

XOMA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XOMA is cheaper than 90.77% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 40.99
XOMA Per share dataXOMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as XOMA's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.5%
EPS Next 3Y37.32%

More info and screens

0

5. Dividend

5.1 Amount

XOMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (9/5/2025, 8:00:02 PM)

35.24

-0.16 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners62.65%
Inst Owner Change4.12%
Ins Owners1.34%
Ins Owner Change-12.45%
Market Cap426.05M
Analysts82
Price Target65.96 (87.17%)
Short Float %2.49%
Short Ratio5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)72.73%
EPS NQ rev (3m)74.52%
EPS NY rev (1m)278.33%
EPS NY rev (3m)165.66%
Revenue NQ rev (1m)8.53%
Revenue NQ rev (3m)22%
Revenue NY rev (1m)6.66%
Revenue NY rev (3m)45.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 194.46
P/S 9.48
P/FCF N/A
P/OCF N/A
P/B 4.61
P/tB 9.06
EV/EBITDA 40.99
EPS(TTM)-1.54
EYN/A
EPS(NY)0.18
Fwd EY0.51%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROCE 4.73%
ROIC 3.73%
ROICexc 6.38%
ROICexgc 10.37%
OM 21.23%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 9.33
Cap/Depr 1425.07%
Cap/Sales 44.89%
Interest Coverage 0.78
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.88
Altman-Z -4.94
F-Score5
WACC10%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y117.66%
EPS Next 2Y44.5%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year78.53%
Revenue Next 2Y41.78%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year179.83%
EBIT Next 3Y51.02%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A